Defense World
14 Feb 2026, 08:24 UTC · 31w ago
Verdict
Headline takes no side. We score FHTX +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Foghorn Therapeutics (FHTX) holds a consensus 'Buy' rating from the nine analysts covering the company.
More positive than 78% of claims this week
Eight out of nine analysts covering FHTX have a positive outlook (Buy or Strong Buy), while only one recommends selling.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has a consensus 'Buy' rating from the majority of covering analysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−36.9%
Price is moving against the score
$3.50 vs $5.55 close before publication (Feb 13) · not market-adjusted
FHTX chart →
